Experiments in human cells connect FOXO3, a gene-regulating protein, with changes in the accessibility of packaged DNA as cells enter a DNA-damage-induced senescent state. The peer-reviewed study also tests chromatin-remodelling machinery and primary astrocytes. Its findings describe molecular responses in cell models, without establishing an effect on human lifespan or clinical ageing.
Reducing FOXO3 prevented part of the DNA-packaging reorganisation that accompanies DNA-damage-induced cellular senescence. The peer-reviewed study examines this gene-regulating protein in human cell systems. Senescence is a state in which cells leave the division cycle. FOXO3 levels rose early as cells entered that state; experiments with primary human astrocytes also linked this protein to reduced DNA damage.[1]
Chromatin is the material in which DNA is packaged with proteins. Researchers measured which regions became accessible and combined this with RNA sequencing and protein-binding assays. Controlled FOXO3 induction changed accessibility and induced genes for chromatin-remodelling proteins, including the SWI/SNF complex. Inhibiting that complex supported its involvement in many of the changes, although the inhibitor may also act on other targets.[1]
The regulatory network in senescent cells differed from that in proliferating cells. Some accessible regions closed and others opened, affecting programmes related to stress, metabolism, protein balance and cell identity. Direct FOXO3 binding has not been demonstrated at every newly accessible site.[1]
The main senescence model used etoposide in the human glioblastoma cell line U87MG. Within three days, DNA synthesis declined; fourteen days of treatment brought cell-cycle exit. The investigators assessed senescence-associated beta-galactosidase alongside proliferation and markers of DNA damage. These experiments examine a particular damage response, rather than lifespan extension or clinical improvement in older people.[1]
